DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: Repotrectinib
Drug: Voriconazole
Drug: Quinidine

First Posted Date: 2024-07-10

Last Posted Date: 2025-03-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT06493409

Locations: 🇺🇸
Fortrea - Daytona Beach, Daytona Beach, Florida, United States

A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Nivolumab + ipilimumab

First Posted Date: 2024-07-05

Last Posted Date: 2024-07-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 400

Registration Number: NCT06487156

Locations: 🇮🇹
Istituto Nazionale Tumori - IRCCS Fondazione G.Pascale, Napoli, Italy

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

Phase 1

Recruiting

Conditions: Healthy Volunteers
Anemia, Sickle Cell

Interventions: Drug: BMS-986470
Drug: Placebo

First Posted Date: 2024-07-01

Last Posted Date: 2025-02-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 184

Registration Number: NCT06481306

Locations: 🇫🇷
Local Institution - 0025, Strasbourg, Alsace, France
🇺🇸
Local Institution - 0008, Birmingham, Alabama, United States
🇺🇸
Local Institution - 0021, La Jolla, California, United States

and more 13 locations

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: BMS-986435

First Posted Date: 2024-06-26

Last Posted Date: 2024-11-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 20

Registration Number: NCT06476821

Locations: 🇨🇳
Local Institution - 0001, Xuhui District, Shanghai, China

A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

Phase 4

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Deucravacitinib

First Posted Date: 2024-06-26

Last Posted Date: 2024-12-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 8

Registration Number: NCT06476834

Locations: 🇺🇸
Local Institution - 0001, Las Vegas, Nevada, United States

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Phase 1

Recruiting

Conditions: High-grade Serous Ovarian Carcinoma (HGSOC)
Uterine Serous Carcinoma (USC)
Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: BMS-986463

First Posted Date: 2024-06-26

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 240

Registration Number: NCT06476808

Locations: 🇨🇦
BC Cancer Vancouver, Vancouver, British Columbia, Canada
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States

and more 3 locations

A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Active, not recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2024-06-11

Last Posted Date: 2025-02-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 260

Registration Number: NCT06452329

Locations: 🇨🇳
Local Institution - 0001, Wuhan, Hubei, China
🇨🇳
Tianjin Happy Life Technology Co., Ltd, Shanghai, China

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Not yet recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies

First Posted Date: 2024-06-07

Last Posted Date: 2024-06-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 55

Registration Number: NCT06448793

Locations: 🇬🇧
Evidera, London, United Kingdom

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy Participants

Interventions: Drug: BMS-986278

First Posted Date: 2024-05-22

Last Posted Date: 2025-01-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 37

Registration Number: NCT06425198

Locations: 🇺🇸
Local Institution - 0002, Tampa, Florida, United States
🇺🇸
Local Institution - 0001, Miami Lakes, Florida, United States
🇺🇸
Local Institution - 0003, Orlando, Florida, United States

and more 1 locations

Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy

Recruiting

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Systemic therapy

First Posted Date: 2024-05-20

Last Posted Date: 2024-10-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 300

Registration Number: NCT06422247

Locations: 🇯🇵
Mebix, Inc, Minato-ku, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy